Effects of Change in Purine Metabolism on Accumulation of Aggregated Proteins in the Cell

我们口服给药最近推出的有效的黄嘌呤氧化还原酶抑制剂，其抑制机制的特点，ALS G1 H-G93 A小鼠。模型实验的结果表明口服非嘌呤类似物XOR抑制剂可显著延缓疾病进展。模型实验表明，这种保护作用可能是由于聚集蛋白的清除率增加，同时嘌呤代谢也发生了变化。

We orally administered recently introduced potent xanthine oxidoreductase inhibitors, whose mechanisms of inhibition are well characterized, to ALS G1H-G93A mice. The results of modelexperiments indicated that orally administered non-purine analogue XOR inhibitors significantly delaythe disease progression. The protective effect is suggested to be due to increased removal ofaggregated protein accompany with change in purine metabolism by the experiment with modelsystems.